• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含1.1%氨基酸的腹膜透析液与含2.27%葡萄糖的腹膜透析液的生物相容性比较。

Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid.

作者信息

Brulez H F, Dekker H A, Oe P L, Verbeelen D, ter Wee P M, Verbrugh H A

机构信息

Department of Internal Medicine, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands.

出版信息

Nephron. 1996;74(1):26-32. doi: 10.1159/000189277.

DOI:10.1159/000189277
PMID:8883016
Abstract

The biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid (AA-PDF) was compared to that of a 2.27% glucose-based peritoneal dialysis fluid (G-PDF). Peritoneal macrophages (PMO), isolated from the peritoneal dialysis (PD) effluents of 10 chronic ambulatory PD patients, were tested for their phagocytosis capacity and peak chemiluminescence response. A subset of PMO was cultured for 24 h with and without lipopolysaccharide (LPS) to study the release of interleukin-1 beta (IL-1 beta) and 8 (IL-8). As control, the interleukin release by blood monocytes of healthy donors was tested. The opsonic activity of the PD effluent was tested as well. Compared to PMO isolated from G-PDF, PMO from AA-PDF showed a significantly better phagocytosis capacity. There was no difference in the peak chemiluminescence response between PMO from AA-PDF and G-PDF. The release of IL-1 beta by unstimulated PMO isolated from the two fluids did not differ. Compared to control monocytes, however, PMO from both fluids showed a considerable spontaneous release of IL-1 beta. When stimulated with LPS, IL-1 beta production by PMO from G-PDF exceeded that of PMO from AA-PDF (p < 0.002). The release of IL-8 by PMO from G-PDF was significantly higher in comparison with PMO from AA-PDF, both spontaneously and after stimulation with LPS (p < 0.02). The opsonic activity of undiluted and to 75% diluted effluents was significantly higher for G-PDF than for AA-PDF (p < 0.01). Thus, compared to the regularly used G-PDF, the phagocytosis capacity as measure for PMO function seems to be better preserved after in vivo exposure to AA-PDF. In addition, the higher release of IL-1 beta and IL-8 by PMO isolated from G-PDF suggests a stronger intra-abdominal activation of PMO, with G-PDF acting as a chemical inflammatory agent. Whether the lower opsonic activity of the AA-PDF is more important for biocompatibility than the other parameters is not clear. Therefore, it is concluded that, although macrophage function is better preserved, it is not proven that the 1.1% AA-PDF studied has an improved biocompatibility compared to 2.27% G-PDF.

摘要

将含1.1%氨基酸的腹膜透析液(AA-PDF)的生物相容性与含2.27%葡萄糖的腹膜透析液(G-PDF)的生物相容性进行了比较。从10例慢性非卧床腹膜透析患者的腹膜透析(PD)流出液中分离出腹膜巨噬细胞(PMO),检测其吞噬能力和化学发光峰值反应。将一部分PMO在有和没有脂多糖(LPS)的情况下培养24小时,以研究白细胞介素-1β(IL-1β)和8(IL-8)的释放。作为对照,检测了健康供体血液单核细胞的白细胞介素释放情况。还检测了PD流出液的调理活性。与从G-PDF中分离出的PMO相比,从AA-PDF中分离出的PMO显示出明显更好的吞噬能力。从AA-PDF和G-PDF中分离出的PMO的化学发光峰值反应没有差异。从两种液体中分离出的未刺激的PMO释放的IL-1β没有差异。然而,与对照单核细胞相比,来自两种液体的PMO都显示出相当数量的IL-1β自发释放。当用LPS刺激时,来自G-PDF的PMO产生的IL-1β超过了来自AA-PDF的PMO(p<0.002)。与来自AA-PDF的PMO相比,来自G-PDF的PMO自发释放和用LPS刺激后释放的IL-8明显更高(p<0.02)。G-PDF的未稀释和稀释至75%的流出液的调理活性明显高于AA-PDF(p<0.01)。因此,与常规使用的G-PDF相比,在体内接触AA-PDF后,作为PMO功能指标的吞噬能力似乎得到了更好的保留。此外,从G-PDF中分离出的PMO释放的IL-1β和IL-8较高,表明PMO在腹腔内的激活更强,G-PDF起到了化学炎症介质的作用。AA-PDF较低的调理活性对生物相容性是否比其他参数更重要尚不清楚。因此,得出的结论是,虽然巨噬细胞功能得到了更好的保留,但与2.27%的G-PDF相比,所研究的1.1%的AA-PDF具有改善的生物相容性这一点尚未得到证实。

相似文献

1
Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid.含1.1%氨基酸的腹膜透析液与含2.27%葡萄糖的腹膜透析液的生物相容性比较。
Nephron. 1996;74(1):26-32. doi: 10.1159/000189277.
2
In vitro effects of amino-acid-based versus glucose-based continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function.
Nephron. 1994;68(3):338-46. doi: 10.1159/000188397.
3
The effect of glycerol-containing peritoneal dialysis fluid on peritoneal macrophage function in vivo.含甘油腹膜透析液对体内腹膜巨噬细胞功能的影响。
Adv Perit Dial. 1991;7:154-7.
4
In vitro compatibility of a 1.1% amino acid containing peritoneal dialysis fluid with phagocyte function.含1.1%氨基酸的腹膜透析液与吞噬细胞功能的体外相容性
Adv Perit Dial. 1994;10:241-4.
5
Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid.
Am J Kidney Dis. 1993 Apr;21(4):411-8. doi: 10.1016/s0272-6386(12)80270-8.
6
In vitro effects of bicarbonate- versus lactate-buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function.碳酸氢盐缓冲与乳酸盐缓冲的持续性非卧床腹膜透析液对腹膜巨噬细胞功能的体外效应
Am J Kidney Dis. 1995 Dec;26(6):924-33. doi: 10.1016/0272-6386(95)90057-8.
7
In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.
Clin Nephrol. 1993 Feb;39(2):75-80.
8
Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.新型腹膜透析液对大鼠腹膜白细胞募集的影响。
Nephron Exp Nephrol. 2005;101(4):e139-45. doi: 10.1159/000087937. Epub 2005 Aug 30.
9
Another reason to restrict the use of a hypertonic, glucose-based peritoneal dialysis fluid: its impact on peritoneal macrophage function in vivo.限制使用基于葡萄糖的高渗腹膜透析液的另一个原因:其对体内腹膜巨噬细胞功能的影响。
Adv Perit Dial. 1991;7:150-3.
10
Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity.腹膜透析液中的渗透剂和缓冲剂:单核细胞细胞因子释放及体外细胞毒性
Am J Kidney Dis. 1997 Sep;30(3):413-22. doi: 10.1016/s0272-6386(97)90287-0.

引用本文的文献

1
The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis.渗透压-代谢平衡策略:腹膜透析中一种新颖且诱人的葡萄糖节约策略。
J Nephrol. 2021 Apr;34(2):503-519. doi: 10.1007/s40620-020-00804-2. Epub 2020 Aug 7.
2
Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.使用新型腹膜透析液预防腹膜透析患者的膜损伤
Int Urol Nephrol. 2007;39(1):299-312. doi: 10.1007/s11255-006-9064-y. Epub 2006 Sep 27.